← Back to Search

Physical Activity Monitoring for Brain Cancer

N/A
Recruiting
Led By Shiao-Pei S Weathers
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosed with a glioma and going to receive at least 4 weeks of RT at MDACC at the Texas Medical Center campus with at least 20 fractions
Karnofsky performance status (KPS) of 70 or above
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether monitoring step count could be a helpful measure of physical activity for newly diagnosed glioma patients undergoing radiation therapy.

Who is the study for?
This trial is for English-speaking patients with a new glioma diagnosis who are starting at least 4 weeks of radiation therapy. Participants must have a good performance status, meaning they can carry out daily activities without significant help, be able to consent, own a smartphone, have Wi-Fi access, and not already use wearable activity trackers.
What is being tested?
The study is testing if using devices like FitBits or pedometers to monitor steps can help understand physical activity levels in patients undergoing radiation therapy for brain tumors. It aims to see if tracking steps could improve life quality and manage symptoms during treatment.
What are the potential side effects?
Since this trial involves non-invasive monitoring tools such as FitBit and questionnaires rather than medications or invasive procedures, there are no direct medical side effects expected from the interventions being tested.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a glioma and will undergo radiation therapy for at least 4 weeks.
Select...
I am able to care for myself but may not be able to do active work.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Consent rate
Fitbit adherence rate
Retention rate
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Group II (FitBit)Experimental Treatment3 Interventions
Patients wear a FitBit for step count monitoring over 6 weeks.
Group II: Group I (pedometer)Active Control3 Interventions
Patients wear a pedometer for step count monitoring over 6 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
FitBit
2017
N/A
~480

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,928 Previous Clinical Trials
41,018,010 Total Patients Enrolled
M.D. Anderson Cancer CenterLead Sponsor
3,067 Previous Clinical Trials
1,802,559 Total Patients Enrolled
Shiao-Pei S WeathersPrincipal InvestigatorM.D. Anderson Cancer Center
4 Previous Clinical Trials
116 Total Patients Enrolled

Media Library

FitBit Clinical Trial Eligibility Overview. Trial Name: NCT04186832 — N/A
Brain Tumor Research Study Groups: Group II (FitBit), Group I (pedometer)
Brain Tumor Clinical Trial 2023: FitBit Highlights & Side Effects. Trial Name: NCT04186832 — N/A
FitBit 2023 Treatment Timeline for Medical Study. Trial Name: NCT04186832 — N/A
~1 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top